Treatment options for managing atherogenic dyslipidemia and fatty liver disease

Manfredi Rizzo*, Giuseppe Montalto, Khalid Al-Rasadi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, while there is reluctance to use statins in patients with suspected or established chronic liver disease. Several other therapeutic options are potentially available, and more data are expected from new peroxisome proliferator-activated receptor agonists and incretin-based therapies.

Original languageEnglish
Pages (from-to)1065-1068
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Issue number8
Publication statusPublished - Jun 2014


  • cardiovascular risk
  • dyslipidemia
  • non-alcoholic fatty liver disease
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Treatment options for managing atherogenic dyslipidemia and fatty liver disease'. Together they form a unique fingerprint.

Cite this